Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.
Official title: 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study in Patients With Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-09-01
Completion Date
2025-12-31
Last Updated
2024-09-25
Healthy Volunteers
No
Conditions
Interventions
68Ga-AAZTA-NI-093
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
Locations (1)
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China